Inhibrx Biosciences, Inc. reports clinical and corporate updates for a pipeline of biologic therapeutic candidates developed with protein engineering platforms. The company’s programs include ozekibart (INBRX-109), a tetravalent death receptor 5 agonist antibody studied in oncology indications including chondrosarcoma, colorectal cancer and Ewing sarcoma, and INBRX-106, a hexavalent OX40 agonist evaluated in immuno-oncology settings such as head and neck squamous cell carcinoma.
Company developments commonly cover clinical trial data, regulatory submissions and designations, scientific conference presentations, quarterly and annual financial results, and capital resources. Inhibrx Biosciences also carries a completed corporate history tied to its 2024 separation from Inhibrx, Inc. following the sale of the INBRX-101 program.
Inhibrx Biosciences (INBX) reported updated Phase 1/2 Ewing sarcoma data showing a 62.7% overall response rate with its ozekibart combination. Ozekibart was combined with irinotecan and temozolomide in relapsed or refractory disease. At the September 18, 2026 cutoff, 60 patients had been treated, including 9 adolescents; 51 were response-evaluable. Responses included 2 complete and 30 partial responses, while disease control reached 86.3%. Median progression-free survival, the time without disease worsening or death, was 6.0 months (95% confidence interval: 4.6–7.4).
Clinical benefit exceeded 6 months in 18 patients, including one with an ongoing partial response beyond 2 years. Inhibrx described safety as manageable, with no evidence of unexpected cumulative liver toxicity, and plans FDA discussions. Separately, the FDA accepted its application for potential ozekibart approval in conventional chondrosarcoma for filing.
Inhibrx Biosciences (INBX) reported a third-quarter 2026 net loss of $38.7 million as higher administrative and other expenses offset lower research spending. Loss per share was $2.46, versus $2.28 a year earlier. Revenue was $2.0 million, versus none, from a non-exclusive patent license to Pfizer. Cash and equivalents reached $199.5 million at September 30, 2026.
Inhibrx plans updated ozekibart Ewing sarcoma results at CTOS on November 19–20, 2026; commercial readiness work for chondrosarcoma is advancing with the regulatory review timeline. The company expects the ordastobart Phase 2 expansion to add approximately 50 HPV-positive oropharyngeal cancer patients, with an initial readout around mid-2027. It plans subsequent FDA alignment and anticipates a Phase 3 confirmatory study. Initial ordastobart lung cancer results are expected in mid-2027. Stockholders' deficit was $85.876 million, versus equity of $7.993 million at year-end 2025.
Inhibrx Biosciences (INBX) will present studies of ordastobart and ozekibart at upcoming scientific conferences, beginning October 25, 2026.
The ESMO Congress in Madrid will feature the phase 2 primary analysis of HexAgon-HN, studying ordastobart with pembrolizumab in head and neck cancer. The MSTS Annual Meeting in Miami on October 29 will cover secondary efficacy endpoints from the phase 2 ChonDRAgon study of ozekibart in conventional chondrosarcoma. At CTOS in Seoul, a November 19 poster will address ozekibart with irinotecan and temozolomide in Ewing sarcoma; a November 20 oral presentation will cover ChonDRAgon subgroup analysis and updated progression-free survival, the time patients live without disease worsening.
Inhibrx (INBX) reported positive primary endpoint results from the randomized Phase 2 HexAgon study of OX40 agonist INBRX-106 plus pembrolizumab in first-line PD-L1–positive metastatic or unresectable recurrent HNSCC. Among 63 evaluable patients, confirmed objective response rate was 48.3% for the combination versus 26.5% for pembrolizumab alone, with complete responses in 13.8% vs 0% of patients, respectively.
Interim median progression-free survival was 9.6 months for the combination versus 4.9 months for control, and six‑month PFS rates were 72.4% vs 42.8%. In HPV+ patients, cORR reached 80.0% with INBRX-106 plus pembrolizumab versus 33.3% for pembrolizumab alone, with a 30.0% complete response rate and 90.0% six‑month PFS; median PFS in this subgroup has not yet been reached. Treatment‑related rash, fatigue and diarrhea were mostly low grade. Inhibrx plans to add ~50 HPV+ OPSCC patients to Phase 2 to support a potential accelerated approval path and then initiate a Phase 3 confirmatory trial.
Inhibrx Biosciences (INBX) will host a live webcast on September 8, 2026 at 5:00 a.m. Pacific Time to present primary endpoint results from the randomized, controlled Phase 2 HexAgon study of INBRX-106 in first-line PD-L1 positive metastatic or unresectable recurrent head and neck squamous cell carcinoma.
The study evaluates INBRX-106, a hexavalent OX40 agonist, plus pembrolizumab versus pembrolizumab monotherapy. Investors can join via webcast or toll-free dial-in, and a replay with slides will be available on the company’s website for 60 days.
Inhibrx Biosciences (Nasdaq: INBX) reported second quarter 2026 results, highlighting clinical progress and a major debt financing. The company entered a Second Amendment to its Loan and Security Agreement with Oxford Finance, providing up to $325.0 million in additional gross proceeds, including $100.0 million funded in July 2026.
The FDA accepted Inhibrx’s BLA for ozekibart (INBRX-109) in conventional chondrosarcoma with a PDUFA goal date of April 14, 2027. New Phase 1 colorectal cancer cohorts were initiated, with interim data expected in Q1 2027. Q2 2026 R&D expense was $23.9 million and G&A was $8.3 million, driving a net loss of $36.7 million or $2.34 per share. Cash and cash equivalents were $133.3 million at June 30, 2026 and $219.5 million as of August 6, 2026, while long‑term debt rose to $176.3 million, and stockholders’ equity turned to a deficit of $53.0 million.
Inhibrx (Nasdaq: INBX) entered into a Second Amendment to its Loan and Security Agreement with Oxford Finance and affiliated lenders, expanding its senior credit facility to an aggregate principal amount of up to $500.0 million.
The amendment adds a new tranche of up to $325.0 million, including a $100.0 million Term C Loan funded at signing and a discretionary Term D Loan of up to $225.0 million available in minimum $50.0 million draws at the lenders’ sole discretion. Before this amendment, Inhibrx had drawn $175.0 million under the facility. In connection with the Term C funding, Inhibrx issued Oxford warrants to purchase 21,457 common shares at a strike price of $93.21 per share, exercisable immediately for ten years.
Inhibrx (Nasdaq: INBX) announced FDA acceptance of its Biologics License Application for Ozekibart (INBRX-109) to treat unresectable or metastatic conventional chondrosarcoma, with a PDUFA goal date of April 14, 2027.
The BLA is backed by the phase 2 ChonDRAgon trial, which met its primary endpoint. Ozekibart reduced risk of disease progression or death by 52% versus placebo (HR 0.479; 95% CI: 0.33, 0.68; P<0.0001), increasing median progression-free survival to 5.52 months vs 2.66 months. If approved, Ozekibart would be Inhibrx’s first commercial product and the first FDA-approved systemic therapy for this disease.
Inhibrx (Nasdaq: INBX) reported first quarter 2026 results and clinical updates for INBRX-106 and ozekibart (INBRX-109).
Cash was $161.7 million, net loss was $33.4 million ($2.15 per share), and a BLA for ozekibart in conventional chondrosarcoma was submitted to the FDA.
Inhibrx (Nasdaq: INBX) reported interim Phase 2 HexAgon data for INBRX-106 plus pembrolizumab in first-line PD-L1–high HNSCC. In 53 response-evaluable patients, the combination showed a 44.0% confirmed objective response rate versus 21.4% with pembrolizumab alone, including three complete responses versus none in control.
Combination treatment produced up to a 15-fold increase in peripheral CD8+ and CD4+ T-cell proliferation and a manageable safety profile without treatment-related deaths. Progression-free survival data are expected in Q4 2026, with a Phase 3 start planned for Q3 2026 and expansion into NSCLC studies.